Document Detail


The potential for clinical use of cannabinoids in treatment of cardiovascular diseases.
MedLine Citation:
PMID:  20946323     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Cannabinoids, the constituents of the marijuana plant and their analogs, have not only neurobehavioral but also cardiovascular effects. Great advances in the last couple of decades have led to better understanding of the physiological effects of the cannabinoids and of their role in various cardiovascular pathologies. The potential therapeutic use of cannabinoids in various cardiac diseases, such as ischemic injury, heart failure, and cardiac arrhythmias, has been studied in animal models. The purpose of this article is to review the physiological cardiovascular properties of cannabinoids and to summarize the knowledge related to their potential therapeutic use.
Authors:
Ronen Durst; Chaim Lotan
Related Documents :
19110503 - Novel aspects of oxidative stress in cardiovascular diseases.
11793633 - Systemic adverse effects of ophthalmic beta-blockers.
16133583 - Cryoglobulinemic purpura in visceral leishmaniasis.
Publication Detail:
Type:  Journal Article     Date:  2010-10-14
Journal Detail:
Title:  Cardiovascular therapeutics     Volume:  29     ISSN:  1755-5922     ISO Abbreviation:  Cardiovasc Ther     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101319630     Medline TA:  Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-22     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Cardiology Division, Hadassah Hebrew University Medical Center, Jerusalem Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac cell therapies: the next generation.
Next Document:  Disruption of coronary vasomotor function: the coronary spasm syndrome.